Table 3.
Treatments on RADs patients with COVID-19.
| Author | Country | Study | N | Cut-off Date | Glucocorticoid | csDMARDs | Antimalarial | t/sDMARDs | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Efficacy | n | Efficacy | n | Efficacy | n | Efficacy | |||||
| Yousaf et al. | USA | Retrospective cohort study | 6,548 | January 20, 2020–June 11, 2020 | NA | 98 | Neutral | NA | 58 | Neutral | ||
| Mathian et al. | France | Case series | 17 | March 29, 2020–April 6, 2020 | NA | NA | 17 | Can not stop the progression to severity | NA | |||
| Teh et al. | Malaysia | Case series | 5 | March 1, 2020 | NA | NA | 5 | Severe course needing aggressive therapy | NA | |||
| Price et al. | USA | Retrospective cohort study | 239 | March 10, 2020–April 21, 2020 | NA | NA | NA | 153 | Survival improved | |||
| Freites Nuñez et al. | Spain | Prospective cohort study | 123 | March 1, 2020–April 24, 2020 | 61 | Neutral | 77 | Neutral | 27 | Neutral | 17 | Risk reduced |
| Galarza-Delgado et al. | México | Case series | 38 | July 2020–August 2020 | NA | 28 | Neutral | 16 | Neutral | NA | ||
| Loarce-Martos et al. | Spain | Retrospective cohort study | 13 | February 1, 2020–May 26, 2020 | NA | NA | NA | 13 | Severe cases increased | |||
| Nuño et al. | Spain | Retrospective cohort study | 122 | February 25, 2020–June 8, 2020 | 47 | Mortality increased | 47 | Hospitalization rates increased | 25 | Neutral | 20 | Hospitalization rates increased |
| Cavagna et al. | Italy | Retrospective cohort study | 53 | Febrary 2020–April 28, 2020 | NA | 53 | Neutral | NA | NA | |||
| Zurita et al. | Ecuador | Case series | 5 | March 3, 2020–May 21, 2020 | NA | NA | 5 | Neutral | NA | |||
| Colaneri et al. | Italy | Retrospective cohort study | 112 | March 14, 2020–March 27, 2020 | NA | NA | NA | 21 | Neutral | |||
| Haberman et al. | USA | Prospective cohort study | 103 | March 3, 2020–May 4, 2020 | 13 | Hospitalization rates increased | NA | NA | 73 | Neutral | ||
| Cordtz et al. | Denmark | Retrospective cohort study | 138 | March 1, 2020–August 12, 2020 | Neutral | NA | Neutral | Neutral | ||||
| Jung et al. | Korea | Retrospective cohort study | 2,066 | Before May, 2020 | NA | NA | 649 | Neutral | NA | |||
| Arleo et al. | USA | Retrospective cohort study | 70 | February 1, 2020–July 31, 2020 | NA | 13 | Hospitalization rates increased | NA | 10 | Hospitalization rates decreased | ||
The studies presented mainly includes treatment regimens after COVID-19 diagnosis. N, numbers of RADs patients infected with COVID-19; n, the number of people who received treatment; NA, data not available; Neutral, there is no particularly beneficial or harmful clinical effect.